{"id":"https://openalex.org/W2891411265","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.9548","title":"BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma.","display_name":"BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma.","publication_year":2016,"publication_date":"2016-05-20","ids":{"openalex":"https://openalex.org/W2891411265","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.9548","mag":"2891411265"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2016.34.15_suppl.9548","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.9548","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.9548","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024264064","display_name":"Michelle L. Rohlfs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle Rohlfs","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027845051","display_name":"Roland L. Bassett","orcid":"https://orcid.org/0000-0002-4534-2042","observed_orcids":["https://orcid.org/0000-0002-4534-2042"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roland L. Bassett","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051115260","display_name":"Carol Lacey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carol Lacey","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084467354","display_name":"Natalie McQuail","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Natalie McQuail","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071012608","display_name":"Urvi Mehta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Urvi Mehta","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022781457","display_name":"Ida John","orcid":"https://orcid.org/0009-0006-0279-1557","observed_orcids":["https://orcid.org/0009-0006-0279-1557"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ida John","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020995725","display_name":"Rinata Simien","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rinata Simien","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039650999","display_name":"Stephanie Tupue","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephanie Tupue","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041285163","display_name":"Tina Dett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tina Karin Dett","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103818472","display_name":"Isabella Claudia Glitza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Isabella Claudia Glitza","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030834372","display_name":"Adi K. Diab","orcid":"https://orcid.org/0009-0000-8944-1547","observed_orcids":["https://orcid.org/0009-0000-8944-1547","https://orcid.org/0000-0002-0153-0244"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adi Diab","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029017725","display_name":"Rodabe Navroze Amaria","orcid":"https://orcid.org/0000-0001-6876-278X","observed_orcids":["https://orcid.org/0000-0001-6876-278X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rodabe Navroze Amaria","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056045921","display_name":"Hussein Abdul-Hassan Tawbi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hussein Abdul-Hassan Tawbi","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048327749","display_name":"Michael A. Davies","orcid":"https://orcid.org/0000-0002-0977-0912","observed_orcids":["https://orcid.org/0000-0002-0977-0912"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael A. Davies","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104110089","display_name":"Wen\u2010Jen Hwu","orcid":"https://orcid.org/0000-0003-1674-0751","observed_orcids":["https://orcid.org/0000-0003-1674-0751"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wen-Jen Hwu","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033798832","display_name":"Patrick Hwu","orcid":"https://orcid.org/0000-0002-8293-1313","observed_orcids":["https://orcid.org/0000-0002-8293-1313","https://orcid.org/0000-0003-0554-2856"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Hwu","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5035218748","display_name":"Sapna Pradyuman Patel","orcid":"https://orcid.org/0000-0003-1339-1517","observed_orcids":["https://orcid.org/0000-0003-1339-1517"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sapna Pradyuman Patel","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"34","issue":"15_suppl","first_page":"9548","last_page":"9548"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.018799999728798866,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9919999837875366},{"id":"https://openalex.org/keywords/braf-inhibitors","display_name":"BRAF inhibitors","score":0.9340000152587891},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.7749999761581421},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6779999732971191},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9850000143051147},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8159999847412109},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.5210000276565552},{"id":"https://openalex.org/keywords/triple-therapy","display_name":"triple therapy","score":0.4869999885559082},{"id":"https://openalex.org/keywords/dual-therapy","display_name":"dual therapy","score":0.5099999904632568},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.33899998664855957},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.8389999866485596},{"id":"https://openalex.org/keywords/real-world-outcomes","display_name":"real-world outcomes","score":0.41999998688697815},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.3569999933242798},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.34599998593330383},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.6840000152587891},{"id":"https://openalex.org/keywords/patient-satisfaction","display_name":"patient satisfaction","score":0.31700000166893005}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9046556949615479},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.7027414441108704},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6371502876281738},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.6194013357162476},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.5823567509651184},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.5483834743499756},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4903145134449005},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.47710803151130676},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.4447585940361023},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4441642463207245},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4330165684223175},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2897742986679077},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.20026639103889465},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.19570395350456238},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2016.34.15_suppl.9548","doi":"https://doi.org/10.1200/jco.2016.34.15_suppl.9548","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2016.34.15_suppl.9548","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2948884915","https://openalex.org/W7170152610","https://openalex.org/W3036170650","https://openalex.org/W2890461491","https://openalex.org/W2948742600","https://openalex.org/W1965480120","https://openalex.org/W2948716731","https://openalex.org/W7162654480","https://openalex.org/W3152678551","https://openalex.org/W2149642154"],"abstract_inverted_index":{"9548":[0],"Background:":[1],"The":[2,38,192,316,366],"treatment":[3],"(tx)":[4],"of":[5,17,41,64,82,99,111,123,140,154,212,217,243,251,271,273,279,294,335,368,375,387,395],"metastatic":[6],"melanoma":[7],"(MM)":[8],"has":[9,46],"met":[10],"with":[11,14,50,57,87,114,120,137,146,151,184,227,277,354],"considerable":[12],"advances":[13],"the":[15,61,95,121,185,210,232,388],"use":[16,81],"targeted":[18,372],"therapy":[19,373],"such":[20],"as":[21,332],"BRAF":[22],"and":[23,28,35,52,97,142,167,177,204,289,304,339,357,381],"MEK":[24],"inhibitors":[25],"(BRAFi,":[26],"MEKi)":[27],"anti-PD1":[29],"(aPD1)":[30],"checkpoint":[31],"agents,":[32,66,141],"pembrolizumab":[33],"(PEMBRO)":[34],"nivolumab":[36],"(NIVO).":[37],"combination":[39],"(combo)":[40],"these":[42,65,72,100],"two":[43],"therapeutic":[44],"classes":[45],"previously":[47],"been":[48,350],"studied":[49,56],"ipilimumab":[51],"is":[53],"currently":[54],"being":[55],"PEMBRO":[58,90,128],"(KEYNOTE-022).":[59],"Given":[60],"commercial":[62],"availability":[63],"many":[67],"providers":[68],"have":[69,133,143,349],"begun":[70],"combining":[71],"agents":[73,89],"for":[74,346],"clinical":[75],"use.":[76],"Thus,":[77],"we":[78],"evaluated":[79],"our":[80,393],"combo":[83,122,159,186,213,233,295],"BRAFi":[84,124,147,187,218,258,264,376],"+/-":[85,125,148,188,219,377],"MEKi":[86,126,149,189,220,266,378],"aPD1":[88,152,260,274,369],"or":[91,129,150,246,254],"NIVO":[92],"to":[93,370],"determine":[94],"tolerability":[96],"efficacy":[98,168],"combined":[101],"tx.":[102,160,214],"Methods:":[103],"We":[104],"performed":[105],"a":[106,144,225,240,333,371],"single-center":[107],"IRB-approved":[108],"retrospective":[109],"review":[110],"patients":[112],"(pts)":[113],"BRAF-positive":[115,384],"mm":[116],"who":[117],"received":[118,134,257,263],"tx":[119,136,234,296,301,306,344],"plus":[127,190],"NIVO.":[130],"Pts":[131],"could":[132],"prior":[135],"either":[138],"class":[139],"run-in":[145,226,241],"drugs":[153],"any":[155],"duration":[156],"before":[157],"concurrent":[158],"Toxicity":[161],"via":[162,169],"adverse":[163],"event":[164],"(AE)":[165],"documentation":[166],"PFS":[170,291],"were":[171,182,198,310,318,326],"captured.":[172],"Results:":[173],"Between":[174],"June":[175],"2014":[176],"December":[178],"2015,":[179],"38":[180],"pts":[181,237,249,280,314,330,342,359],"treated":[183],"aPD1.":[191,268],"median":[193,290],"age":[194],"was":[195,275,286,297],"54,":[196],"52%":[197],"male,":[199],"68%":[200],"had":[201,206,224,239,343],"M1c":[202],"disease":[203],"24%":[205],"elevated":[207],"LDH":[208],"at":[209,362],"time":[211],"Run-in":[215],"consisted":[216],"in":[221,312,328,383],"63%,":[222],"34%":[223],"aPD1;":[228],"one":[229],"pt":[230],"started":[231],"concurrently.":[235],"Eight":[236],"(21%)":[238],"period":[242],"4":[244,329],"wks":[245,253],"less,":[247],"12":[248],"(32%)":[250],"6":[252],"less.":[255],"58%":[256],"+":[259,265,267],"while":[261],"42%":[262],"Mean":[269],"number":[270],"doses":[272],"10,":[276],"majority":[278,317],"(79%)":[281],"receiving":[282],"PEMBRO.":[283],"Median":[284],"follow-up":[285],"4.9":[287],"mos":[288,299,303],"from":[292],"start":[293],"7.6":[298],"(doublet":[300],"8.5":[302],"triplet":[305],"7.2":[307],"mos).":[308],"AEs":[309,325,353],"noted":[311],"28":[313],"(74%).":[315],"Grade":[319],"(G)":[320],"1-2,":[321],"commonly":[322],"fatigue.":[323],"G3-4":[324],"seen":[327],"(11%)":[331],"result":[334],"rash,":[336],"nausea/vomiting,":[337],"fever":[338],"chills.":[340],"No":[341],"held":[345],"hepatotoxicity;":[347],"there":[348],"no":[351],"G5":[352],"this":[355,396],"combo,":[356],"all":[358],"remain":[360],"alive":[361],"last":[363],"follow-up.":[364],"Conclusions:":[365],"addition":[367],"regimen":[374],"appears":[379],"safe":[380],"well-tolerated":[382],"MM.":[385],"Results":[386],"prospective":[389],"KEYNOTE-022":[390],"will":[391],"further":[392],"understanding":[394],"combo.":[397]},"counts_by_year":[{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-02T10:15:12.560889","created_date":"2018-09-27T00:00:00"}